Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm.

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Disease-modifying agents (DMAs) are crucial for managing MS progression and symptoms.

Purpose of the Study:

• To critically assess the current landscape of disease-modifying agents for multiple sclerosis (MS).
• To analyze the impact of newly approved and late-stage development agents on current MS treatment strategies.

Main Methods:

• Review of recent clinical studies and real-world data on MS treatments.
• Analysis of treatment algorithms and emerging therapeutic options.

Main Results:

• Early initiation of highly effective therapies may offer greater benefits in relapsing MS.
• Highly effective therapies, including ocrelizumab and siponimod, demonstrate efficacy in various MS types.
• New agents like ofatumumab and S1P receptor modulators are in late-stage development.
• Immune reconstitution therapies (cladribine, alemtuzumab) and autologous hematopoietic stem-cell transplantation are emerging options.

Conclusions:

• The development of disease-modifying agents for MS is advancing rapidly.
• Current treatment algorithms require updates to incorporate new therapeutic advancements for optimal MS management.